Metformin + Exercise for Metabolic Syndrome
Trial Summary
What is the purpose of this trial?
Arterial disease is the leading cause of morbidity/mortality in Metabolic syndrome (MetS). This occurs early as evidenced by arterial dysfunction that, in turn, raises blood pressure and glucose. Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular risk. However, the optimal exercise dose to be combined with metformin for additive effects on vascular function is unknown. Based on the investigator's preliminary work, the overall hypothesis is that metformin blunts adaptation following high intensity exercise training (HiEx) by lowering mitochondrial derived oxidative stress signaling. The investigators further hypothesize that low intensity exercise (LoEx) training combined with metformin will promote additive effects on vascular function compared to LoEx or HiEx+metformin, and maintain/improve non-exercise physical activity patterns. In this double-blind trial, obese 30-60y MetS participants will be randomized to: 1) LoEx+placebo; 2) LoEx+metformin, 3) HiEx+placebo; or 4) HiEx+metformin for 16 weeks.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are taking medications that affect heart rate and rhythm or active weight suppression medications, you may not be eligible to participate.
What evidence supports the effectiveness of the treatment combining metformin and exercise for metabolic syndrome?
Is the combination of metformin and exercise safe for humans?
How does the treatment of Metformin combined with exercise differ from other treatments for metabolic syndrome?
The combination of Metformin and exercise for treating metabolic syndrome is unique because it targets insulin resistance, a key factor in the condition, by using both a medication that improves glucose tolerance and physical activity that enhances fitness and body composition. However, there is conflicting evidence on whether Metformin might reduce the benefits of exercise, making this combination a novel area of study compared to using either treatment alone.1291011
Research Team
Steven K Malin, PhD
Principal Investigator
Rutgers, The State University of New Jersey
Eligibility Criteria
Adults aged 40-80 with Metabolic Syndrome, not currently on metformin or engaging in significant exercise, who have a BMI between 25 and 47. Participants should have risk factors like high blood pressure, large waist circumference, or a family history of diabetes but cannot be diabetic themselves. Excludes those with serious health conditions, non-English speakers, recent smokers, pregnant/nursing women, and anyone on certain heart medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 16 weeks of exercise training combined with either metformin or placebo, with varying exercise intensities
Follow-up
Participants are monitored for changes in vascular and metabolic insulin sensitivity
Treatment Details
Interventions
- Exercise
- Metformin
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator